ZNS GmbH Zentrum fuer Neurologisch-Psychiatrische Studien Gutachten und medizinische Fortbildung Siegen — Clinical Trial Site

10 Registered trials

0 Currently recruiting

Organisation

ZNS GmbH Zentrum fuer Neurologisch-Psychiatrische Studien Gutachten und medizinische Fortbildung Siegen

Location

Siegen, Germany

Identifier

ORG-100044280

Address

Weidenauer Strasse 84, Weidenau, 57076, Germany

Departments

-
#1912
#3203
1109
6701: ZNS GmbH
N/A
Neurology
Weidenauer Strasse 120
Zentrum für Neurologisch-Psychatrische Studien

Clinical trials at this site (10)

Search interface

A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended

2024-513435-24-01 Neuropathic Pain; Distal Sensory Polyneuropathy 4 2025-06-03
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 relapsing multiple sclerosis (RMS) 5 2021-07-23
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv… Ended

2023-507493-41-00 relapsing multiple sclerosis (RMS) 5 2020-08-04
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5